GlassScriptPhysician profile
Uma H Gowda
NPI 1013976570
$40,456.67
in general payments reported to CMS, 2019-2025
37 companies · $3,638 in 2025
The $3,638 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,719 · 2020: $5,571 · 2021: $2,818 · 2022: $18K · 2023: $4,436 · 2024: $3,306 · 2025: $3,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,670 · Food and Beverage: $3,841 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,670.00 |
| Food and Beverage | $3,841.24 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Education | $143.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16,770.67 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $6,950.68 | 2019-2025 | Calquence, Lynparza, Tagrisso |
| Karyopharm Therapeutics INC. | $4,213.62 | 2020-2021 | |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $1,625.00 | 2022 | |
| Beigene USA, INC. | $1,578.03 | 2022-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $1,220.23 | 2020-2025 | Rezlidhia, Gavreto, Tavalisse |
| Tesaro, INC. | $1,029.69 | 2019 | |
| Janssen Biotech, INC. | $850.38 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Pfizer INC. | $803.01 | 2019-2025 | |
| Genentech USA, INC. | $314.82 | 2019-2025 | Lunsumio, Polivy |
| Amgen INC. | $308.75 | 2019-2023 | Kyprolis |
| Seagen INC. | $289.89 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $237.98 | 2021-2024 | Opdivo |
| Daiichi Sankyo INC. | $221.41 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $211.15 | 2019-2024 | Keytruda |
| Astellas Pharma US INC | $204.93 | 2022-2025 | Padcev |
| Novartis Pharmaceuticals Corporation | $204.33 | 2019-2024 | |
| Array Biopharma INC | $158.08 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Intuitive Surgical, INC. | $152.54 | 2022 | |
| Boston Scientific Corporation | $149.93 | 2024 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Sirtex Medical INC | $148.50 | 2019 | |
| Medtronic USA, INC. | $144.97 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $127.09 | 2025 | Onivyde |
| Genzyme Corporation | $124.99 | 2019 | |
| Agios Pharmaceuticals, INC. | $124.99 | 2025 | Pyrukynd |
| Incyte Corporation | $124.93 | 2022-2025 | Monjuvi, Pemazyre |
| Alexion Pharmaceuticals, INC. | $98.60 | 2022 | |
| Abbvie INC. | $95.81 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $89.42 | 2025 | Libtayo |
| Celgene Corporation | $34.34 | 2025 | Reblozyl |
| Blueprint Medicines Corporation | $26.23 | 2020 | |
| Biocon Biologics INC | $23.54 | 2025 | Ogivri |
| Beone Medicines USA, INC. | $22.72 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $19.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2019 | |
| Eisai INC. | $12.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.